Cognitive rehabilitation for people with post-COVID-19 syndrome
Cognitive Strategy Training in Post-COVID-19 Syndrome: a Feasibility Trial
This study is testing whether a remote cognitive rehabilitation program can help people with memory and thinking problems after having COVID-19 improve their daily activities and overall quality of life.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 65 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | University of Missouri-Columbia Academic / other |
| Locations | 1 site (Columbia, Missouri) |
| Trial ID | NCT06136871 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the feasibility of delivering the CO-OP (Cognitive Orientation to daily Occupational Performance) approach remotely to individuals suffering from cognitive impairments due to post-COVID-19 syndrome (PCS). It will assess the impact of CO-OP on participants' activity performance, cognitive function, and quality of life compared to an inactive control group. The research hypothesizes that CO-OP will significantly improve these outcomes for individuals who self-report cognitive symptoms following COVID-19 infection. The study will utilize metacognitive strategy training to help participants develop effective strategies for managing their daily activities.
Who should consider this trial
Good fit: Ideal candidates are individuals who have self-reported cognitive symptoms for at least six weeks following a COVID-19 infection and have specific activity performance goals.
Not a fit: Patients with severe neurological or psychiatric conditions, dementia, untreated sleep apnea, or severe depressive symptoms may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly enhance the daily functioning and quality of life for patients experiencing cognitive impairments after COVID-19.
How similar studies have performed: Previous studies have shown positive effects of the CO-OP approach in other populations, suggesting potential success in this novel application for post-COVID-19 syndrome.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * self-reported cognitive symptoms persisting for at least 6 weeks following COVID-19 infection (Cognitive Failures Questionnaire (CFQ) score \>43) * self-identified activity performance goals per the Canadian Occupational Performance Measure (COPM) * documented prior diagnosis of COVID-19 * read, write, and speak English fluently * ability to provide valid informed electronic consent Exclusion Criteria: * diagnosis of severe neurological or psychiatric condition(s) * dementia symptoms as indicated by a score of \<23 on the Montreal Cognitive Assessment (MoCA) * untreated sleep apnea (≥5 on the STOPBANG) * prior cancer treatment * severe depressive symptoms (\>21 on the Patient Health Questionnaire-9)
Where this trial is running
Columbia, Missouri
- University of Missouri Department of Occupational Therapy — Columbia, Missouri, United States (Recruiting)
Study contacts
- Principal investigator: Anna E Boone, PhD, OTR/L — University of Missouri Occupational Therapy
- Study coordinator: Anna E Boone, PhD, OTR/L
- Email: booneae@umsystem.edu
- Phone: 573-882-7023
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.